EarlySign Expands Collaboration with Roche in Supporting the Early Detection of Colon Cancer

ColonFlag is included in the Roche navify® Algorithm Suite, a managed ecosystem of medical value algorithms supporting enhanced clinical decision making

TEL AVIV, Israel, May 1, 2023 /PRNewswire/ -- Medial EarlySign (earlysign.com), a pioneering company developing AI-based clinical predictive analytics, announced at the recent HIMSS Conference a new agreement with Roche, which will allow for EarlySign ColonFlag to be offered within the navify® Algorithm Suite from Roche Diagnostics.  ColonFlag is a computational clinical software model intended to help healthcare providers identify individuals at elevated risk for colon cancer who warrant further evaluation. Currently, leading health care organizations and health systems across the globe have deployed ColonFlag. In the US, the ColonFlag algorithm is marketed as LGI-Flagtm, as an indication for lower Gastrointestinal (GI) disorders.

The addition of ColonFlag to the navify® portfolio of digital solutions represents continued growth and builds on the development agreements between EarlySign and Roche to support the early detection of gastric and lung cancer. 

"The ambition of our collaborative ecosystem is to simplify and broaden access to clinical algorithms for better clinical decisions. This means a major step towards EarlySign's mission of keeping people healthier for longer while also striving to reduce costs and improve care," said Ori Geva, CEO and co-founder of EarlySign. "Our growing collaboration with Roche will give us the opportunity to put patients first by providing proven clinical algorithms that can be used by healthcare providers in every step of the patient journey, supporting better patient management."

"We welcome ColonFlag to our digital ecosystem of medical algorithms where our goal is to strive for a more connected, secure, efficient and flexible healthcare system, where digital technologies unlock new possibilities for better care," commented Cristin Hubbard, Global Head of Partnering at Roche Diagnostics. "With advanced digital solutions for informed personalized care, ColonFlag as part of the navify® Algorithm Suite will support physicians to define and provide more targeted and better treatment options for patients."

About Medial EarlySign

Medial EarlySign's clinical machine learning software solutions help healthcare stakeholders keep patients healthier longer. With EarlySign's models, healthcare clients derive actionable and personalized clinical insights from massive amounts of health data leading to potential improvements in meaningful care, outcomes, and optimal diagnostic and medication use. The company's purpose-built development environment enables better decision making with accurate, explainable models supported by peer-reviewed research published by internationally recognized health organizations and hospitals.

Amongst numerous publications and studies, EarlySign was named a winner of the CMS AI Health Outcomes Challenge. Founded in 2013, Medial EarlySign is headquartered in Tel Aviv, Israel. For more information, please visit: https://earlysign.com/. Follow Medial EarlySign on LinkedIn: Medial EarlySign 

EarlySign Media Contact:
Darrell Atkin
[email protected]
+1.760.390.6036

SOURCE Medial EarlySign